<DOC>
	<DOCNO>NCT01877954</DOCNO>
	<brief_summary>The primary aim study compare absolute relative effectiveness asthma management paediatric patient UK inhale corticosteroid ( ICS ) maintenance therapy extra-fine HFA-BDP ( QvarÂ® ) pressurise meter dose inhaler ( pMDI ) compare fluticasone propionate ( FP ) pMDI .</brief_summary>
	<brief_title>Qvar v FP Pediatrics</brief_title>
	<detailed_description>Comparison asthma control extrafine-particle hydrofluoroalkane-beclometasone ( EF HFA-BDP ) v fluticasone propionate ( FP ) paediatric patient ( 5-11year old ) . Patients identify General Practice Research Database ( GPRD ) Optimum Patient Care Research Database ( OPCRD ) . Two analysis conduct : 1 . Comparison outcomes achieve EF HFA-BDP FP 5-6year old patient achieve 7-11yr old patient . 2 . Comparison outcomes achieve EF HFA-BDP use without spacer achieve standard particle fluticasone propionate ( FP ) use spacer .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Aged : 511 year 2 . Evidence asthma ( diagnostic code and/or current asthma therapy ) ; 3 . Have least one year uptostandard ( UTS ) baseline data ( stepup FP/SAL occur ) least one year UTS outcome data ( follow IPD ) . 1 . Had chronic respiratory disease , except asthma , time ; and/or 2 . Patients maintenance oral steroid baseline year</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>hydrofluoroalkane beclomethasone</keyword>
	<keyword>fluticasone</keyword>
	<keyword>paediatrics</keyword>
	<keyword>real-life</keyword>
	<keyword>observational</keyword>
	<keyword>primary care</keyword>
</DOC>